Efficacy of interferon therapy in patients with hepatitis B virus‐related primary hepatic carcinoma after transcatheter arterial chemoembolization

Objective Intrahepatic recurrence is the major cause of death among patients with hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). There are few reports of adjuvant interferon (IFN) therapy for HBV‐related HCC after TACE. The aim o...

Full description

Saved in:
Bibliographic Details
Published in:Precision radiation oncology 2018-09, Vol.2 (3), p.76-84
Main Authors: Xin, Meng, Feng, Dongfeng, Yin, Beibei, Li, Yan
Format: Article
Language:English
Subjects:
Antigens
Cancer therapies
Hepatitis
Hepatitis B
hepatitis B virus
hepatocellular carcinoma
Interferon
Liver cancer
Liver diseases
Medical imaging
Medical prognosis
overall survival rate
Patients
recurrence rate
Studies
transcatheter arterial chemoembolization
Tumors
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective Intrahepatic recurrence is the major cause of death among patients with hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE). There are few reports of adjuvant interferon (IFN) therapy for HBV‐related HCC after TACE. The aim of the present study was to evaluate the effect of IFN therapy in patients with HBV‐related primary HCC after TACE. Methods The study included 138 patients with HBV‐related unresectable HCC recruited from May 2014 to October 2015. Patients were randomly assigned to the control (n = 68, TACE) or observation group (n = 70, TACE + IFN), and were followed up for more than 24 months. Clinical indexes (cellular immune function, hepatic function, HBV DNA levels, hepatitis B e‐antigen seroconversion and conversion rate, and hepatic fibrosis) before and after treatment, as well as the short‐term curative effect and recurrence, were compared between the groups. To assess the effect of treatment based on the Modified Response Evaluation Criteria in Solid Tumors, progression‐free survival, overall survival, and adverse events were recorded and compared. Results After treatment, the percentages of CD3+, CD4+, CD4+/CD8+, and natural killer cells were significantly increased in the observation group (TACE + IFN group; P 
ISSN:2398-7324
2398-7324
DOI:10.1002/pro6.53